Wed 6/3/2020 07:01 ET
DJIA25742.65270.301.05%TELCO170.251.120.66%GOLD1731.6018.351.06%Shanghai2923.372.050.07%
S&P 5003080.8225.260.82%BANKS345.741.940.56%OIL35.341.634.61%BITCOIN9611.4087.460.91%
NASDAQ9608.3856.690.59%PHARM612.807.351.20%US/EU1.120.000.27%Futures3057.2519.260.63%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit (Caladrius Biosciences, Inc - CLBS)    Stock Due Diligence for All

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add CLBS
  
From: SunTzu772 (Rep: 1326) reply to stormcatDate: 05/22/2020 14:45
Forum: Wall Street Pit - Msg #2848806 - List CLBS msgs Thread #674157564 (Rec: 8)
Re: Billion+ dollar hedge fund founders must have their reasons.

You bet storm....Armistice has been sitting on the bid all week soaking up sells as volume keeps building.

If CLBS119 is proven to repair Covid-lung where the virus destroys lung vasculature after patients come off ventilators there could be a zero added on to the end of the first 2.

CLBS16 ph3 --> FDA approval will be a game-changer.


--------

"Caladrius is developing cellular therapies for ischemic diseases. Its CD34 technology platform uses a patient’s own CD34+ cells for self-repair and restoration.

“Unlike conventional cell therapies, the CD34+ cell platform eliminates the need for genetic modifications, cell expansion, and offers a faster, compatible, localized, cost-effective potential cell-therapy,” writes analyst Kumaraguru Raja.

Caladrius has three candidate drugs – CLBS12, CLBS14 and CLBS16 – in clinical studies and recently filed an IND for a new drug candidate, CLBS119, for treatment of COVID-19 patients with severe respiratory distress related to infection and ventilation.

Mr. Raja said CLBS12 is being developed for the treatment of critical limb ischemia, and is a recipient of Japanese breakthrough designation for early conditional approval in Japan. “The anticipated completion for this study is the end of 2020 or early 2021, and potential commercialization of CLBS12 in late 2021/early 2022,” he added.

“We believe that the company presents a favorable risk-reward proposition and see potential for partnerships, or collaborations with pipeline advance and clinical success,” Mr. Raja said."

https://biotuesdays.com/2020/05/22/brookline-starts-caladrius-biosciences-at-buy-pt-7/



------------------- "Opportunities multiply as they are seized" -- Sun Tzu circa 500 B.C. -------------------



Reply to stormcat - Msg #2848666 - 05/22/2020 10:27

Re: Billion+ dollar hedge fund founders must have their reasons.

Popped to 2.25 now back filling...traders will find this SUN great DD
NOTE: This message has been revised 1 time. Read original version of this message.
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser SunTzu772: Reward | Watch | IgnoreCLBS: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add CLBS
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.